Pyxis Oncology grants director 46,000 stock options

Pyxis Oncology, Inc. (PYXS) reported that director Jakob Dupont received a grant of 46,000 stock options on August 20, 2026.

Rhea-AI Filing Summary

Pyxis Oncology, Inc. (PYXS) reported that director Jakob Dupont received a grant of 46,000 stock options on August 20, 2026. The options have an exercise price of $3.12 per share, expire on August 20, 2036, and will vest in equal monthly installments through October 31, 2026, subject to his continued service. Following this award, he holds 46,000 options directly.

Insider Trade Summary

Grant/Award: 46,000 shares

Grant/Award 1 txn

Insider Dupont Jakob

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	46,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 46,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option will vest in equal monthly installments through October 31, 2026, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Stock options granted: 46,000 options Exercise price: $3.12 per share Option expiration date: August 20, 2036 +2 more

5 metrics

Stock options granted 46,000 options Grant to director Jakob Dupont on August 20, 2026

Exercise price $3.12 per share Exercise price of the granted stock options

Option expiration date August 20, 2036 Expiration of the granted stock options

Underlying shares 46,000 shares of Common Stock Shares underlying the stock option grant

Shares following transaction 46,000 options Total options held by Jakob Dupont after the award

Key Terms

Stock Option (Right to Buy), exercise price, vesting, underlying security

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 3.1200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to this option will vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PYXS disclose for Jakob Dupont?

Pyxis Oncology disclosed that director Jakob Dupont received a grant of 46,000 stock options on August 20, 2026, as a compensation-related award, with all options held directly after the transaction.

What is the exercise price of Jakob Dupont’s new PYXS stock options?

The granted stock options have an exercise price of $3.12 per share, allowing Jakob Dupont to buy Pyxis Oncology common stock at that price once the options vest and are exercised.

When do Jakob Dupont’s PYXS stock options vest?

The 46,000 Pyxis Oncology stock options will vest in equal monthly installments through October 31, 2026, contingent on Jakob Dupont’s continued service through each applicable vesting date.

What is the expiration date of the PYXS options granted to Jakob Dupont?

The stock options granted to Jakob Dupont expire on August 20, 2036, giving him up to that date to exercise vested options, subject to the grant’s other terms.

How many PYXS options does Jakob Dupont hold after this grant?

Following this award, Jakob Dupont holds 46,000 stock options for Pyxis Oncology common stock directly, according to the reported post-transaction holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2026 - 06:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dupont Jakob

(Last) (First) (Middle)

C/O PYXIS ONCOLOGY, INC.

321 HARRISON AVENUE, 11TH FL. SUITE 1

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pyxis Oncology, Inc. [ PYXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.12	08/20/2026		A		46,000		(1)	08/20/2036	Common Stock	46,000	$0	46,000	D

Explanation of Responses:

1. The shares subject to this option will vest in equal monthly installments through October 31, 2026, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Jitendra Wadhane, Attorney-in-Fact for Jakob Dupont	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)